Differential release of cardiac enzymes after percutaneous coronary intervention

Catheterization and Cardiovascular Interventions

Volumn 65, Issue 1, 2005, Pages 19-24

  Matthews, Mark A ^a   Kunselman, Susan J ^b   Gascho, Joseph A ^a   Gilchrist, Ian C ^a,c  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Calcium channel blockers; Coronary arteriosclerosis; Myocardial infarction; Nitroglycerin

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CREATINE KINASE; GLYCERYL TRINITRATE; HEART ENZYME; NICARDIPINE; VERAPAMIL;

ADULT; AGED; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CREATINE KINASE BLOOD LEVEL; FEMALE; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN EXPRESSION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CALCIUM CHANNEL BLOCKERS; CORONARY VESSELS; CREATINE KINASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NITROGLYCERIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS;

EID: 17944404935     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20365     Document Type: Article

References (23)

1. Waksman R, Ghazzal ZM, Baim DS, et al. Myocardial infarction as a complication of new interventional devices. Am J Cardiol 1996;78:751-756.
2. Califf R, Abdelmeguid A, Kuntz R, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31: 241-251.
3. Abbo KM, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995;75:778-782.
4. Piana R, Paik G, Moscucci M, et al. Incidence and treatment of "no-reflow" after percutaneous coronary intervention. Circulation 1994;89:2514-2518.
5. Iwakura K, Ito H, Takiuchi S, et al. Alternation in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction. Circulation 1996;94: 1269-1275.
6. Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001;103:2780-2783.
7. Gilchrist IC, Cantor WJ, Blankenship JC, et al. Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience. Circulation 2000;102: II640-II641.
8. Bonderman D, Teml A, Jakowitsch J, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002;99:2794-2800.
9. Kotani J-I, Nanto S, Mintz GS, et al. Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation 2002;106:1672-1677.
10. Werner GS, Lang K, Kuehnert H, et al. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002;57: 444-451.
11. Littel RC, Stroup GA, Wolfinger RD, et al. SAS system for mixed models. Cary, NC: SAS Institute; 1996.
12. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA 2002;99:8306-8311.
13. Kloner R, Ganote C, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974;54:1496-1508.
14. Reffelmann T, Kloner RA. The "no-reflow" phenomenon: basic science and clinical correlates. Heart 2002;87:162-168.
15. Pomerantz R, Kuntz R, Diver D, et al. Intracoronary verapamil for the treatment of distal microvascular coronary spasm following percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn 1991;24:283-285.
16. Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med 1983;307:1618-1627.
17. Dhein S, Salameh A, Berkels R, et al. Dual mode of action of dihydropyridine calcium antagonists: a role for nitric oxide. Drugs 1999;58:397-410.
18. van Breeman C, Mangel A, Fahim M, et al. Selectivity of calcium antagonistic action in vascular smooth muscle. Am J Cardiol 1982;49:507-510.
19. Blankenship JC, Islam MA, Wood GC, Iliadis EA. Angiographic adverse vents during percutaneous coronary intervention fail to predict creatine kinase-MB elevation. Catheter Cardiovasc Interv 2004;63:31-41.
20. Brener SJ, Lytle BW, Schneider JP, et al. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 2002;40: 1961-1967.
21. Gibson CM, Cannon CP, Murphy SA, Susan J, Marble HVB, Braunwald E. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002;105: 1909-1913.
22. Greer IA, Walker JJ, McLaren M, et al. Inhibition of whole blood platelet aggregation by nicardipine, and synergism with prostacyclin in-vitro. Thromb Res 1986;41:509-518.
23. Wijeysundera DN, Beattie S, Rao V, et al. Calcium antagonists reduce cardiovascular complications after cardiac surgery. Circulation 2003;41:1496-1505.